Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.54
RTRX's Cash to Debt is ranked lower than
67% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. RTRX: 0.54 )
Ranked among companies with meaningful Cash to Debt only.
RTRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 3.21 Max: No Debt
Current: 0.54
Equity to Asset 0.58
RTRX's Equity to Asset is ranked lower than
57% of the 722 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. RTRX: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
RTRX' s Equity to Asset Range Over the Past 10 Years
Min: -3.16  Med: 0.01 Max: 0.63
Current: 0.58
-3.16
0.63
Interest Coverage N/A
RTRX's Interest Coverage is ranked higher than
65% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.15 vs. RTRX: N/A )
Ranked among companies with meaningful Interest Coverage only.
RTRX' s Interest Coverage Range Over the Past 10 Years
Min: 175.78  Med: No Debt Max: No Debt
Current: N/A
F-Score: 4
M-Score: -2.53
WACC vs ROIC
10.35%
-13.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -47.15
RTRX's Operating margin (%) is ranked lower than
85% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.25 vs. RTRX: -47.15 )
Ranked among companies with meaningful Operating margin (%) only.
RTRX' s Operating margin (%) Range Over the Past 10 Years
Min: -47.15  Med: 345.21 Max: 2105.03
Current: -47.15
-47.15
2105.03
Net-margin (%) -33.79
RTRX's Net-margin (%) is ranked lower than
83% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. RTRX: -33.79 )
Ranked among companies with meaningful Net-margin (%) only.
RTRX' s Net-margin (%) Range Over the Past 10 Years
Min: -33.79  Med: 345.99 Max: 2059.37
Current: -33.79
-33.79
2059.37
ROE (%) -13.63
RTRX's ROE (%) is ranked lower than
77% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.55 vs. RTRX: -13.63 )
Ranked among companies with meaningful ROE (%) only.
RTRX' s ROE (%) Range Over the Past 10 Years
Min: -13.63  Med: 89.25 Max: 89.25
Current: -13.63
-13.63
89.25
ROA (%) -8.04
RTRX's ROA (%) is ranked lower than
76% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. RTRX: -8.04 )
Ranked among companies with meaningful ROA (%) only.
RTRX' s ROA (%) Range Over the Past 10 Years
Min: -575  Med: -329.94 Max: 36.19
Current: -8.04
-575
36.19
» RTRX's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

RTRX Guru Trades in Q4 2015

Joel Greenblatt Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 26,665 sh (-34.66%)
» More
Q1 2016

RTRX Guru Trades in Q1 2016

Jim Simons 76,600 sh (New)
Paul Tudor Jones 24,165 sh (-9.38%)
» More
Q2 2016

RTRX Guru Trades in Q2 2016

Steven Cohen 174,800 sh (New)
Paul Tudor Jones 37,967 sh (+57.12%)
Jim Simons Sold Out
» More
Q3 2016

RTRX Guru Trades in Q3 2016

Lee Ainslie 148,661 sh (New)
Paul Tudor Jones 66,213 sh (+74.40%)
Steven Cohen 150,800 sh (-13.73%)
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NAS:RMTI, NAS:ZGNX, OTCPK:VEGPF, NAS:AERI, OTCPK:HAWPF, AMEX:TXMD, NAS:ASMB, OTCPK:DKNMF, NAS:HCM, NAS:OASM, NAS:NBRV, OTCPK:BIOYF, NAS:ALIM, AMEX:NNVC, NAS:PRPH, NAS:NVGN, AMEX:AXN, OTCPK:CHEXF, OTCPK:INNV, NAS:IMNP » details
Traded in other countries:17R.Germany,
Retrophin Inc is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases.

Retrophin Inc was incorporated as Desert Gateway, Inc. as an Oklahoma corporation on February 8, 2008. On February 14, 2013, the Company changed its name to Retrophin, Inc. The Company is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It is developing Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection, which it refers to as aiding milk let-down, and for the treatment of Schizophrenia and Autism. It is also developing RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone, or ACTH, for the treatment of Infantile Spasms, or IS, and Nephrotic Syndrome, or NS. It is developing sparsentan, formerly known as RE-021, a dual acting receptor antagonist of angiotensin and endothelin receptors, for the treatment of focal segmental glomerulosclerosis, or FSGS. The Company competes with Genentech, GlaxoSmithKline, Roche, Novartis, Pfizer, Boehringer Ingelheim, Sanofi, BioMarin, Sarepta, Vertex, and Jazz Pharmaceuticals. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.

Ratios

vs
industry
vs
history
P/B 2.59
RTRX's P/B is ranked higher than
56% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. RTRX: 2.59 )
Ranked among companies with meaningful P/B only.
RTRX' s P/B Range Over the Past 10 Years
Min: 1.43  Med: 2.41 Max: 8.33
Current: 2.59
1.43
8.33
P/S 6.35
RTRX's P/S is ranked lower than
71% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. RTRX: 6.35 )
Ranked among companies with meaningful P/S only.
RTRX' s P/S Range Over the Past 10 Years
Min: 1.87  Med: 3.72 Max: 22.84
Current: 6.35
1.87
22.84
POCF 295.65
RTRX's POCF is ranked lower than
98% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.41 vs. RTRX: 295.65 )
Ranked among companies with meaningful POCF only.
RTRX' s POCF Range Over the Past 10 Years
Min: 156.5  Med: 226.76 Max: 341.55
Current: 295.65
156.5
341.55

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.28
RTRX's Price/Tangible Book is ranked lower than
69% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. RTRX: 6.28 )
Ranked among companies with meaningful Price/Tangible Book only.
RTRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.16  Med: 5.12 Max: 6.84
Current: 6.28
3.16
6.84
Price/Projected FCF 6.65
RTRX's Price/Projected FCF is ranked lower than
72% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. RTRX: 6.65 )
Ranked among companies with meaningful Price/Projected FCF only.
RTRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.41  Med: 6.03 Max: 7.24
Current: 6.65
4.41
7.24
Price/Median PS Value 1.67
RTRX's Price/Median PS Value is ranked lower than
75% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. RTRX: 1.67 )
Ranked among companies with meaningful Price/Median PS Value only.
RTRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 1 Max: 5.91
Current: 1.67
0.57
5.91
Earnings Yield (Greenblatt) (%) -7.12
RTRX's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. RTRX: -7.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RTRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.5  Med: 16.85 Max: 22.6
Current: -7.12
-7.5
22.6

More Statistics

Revenue (TTM) (Mil) $123.6
EPS (TTM) $ -1.63
Beta1.17
Short Percentage of Float19.25%
52-Week Range $11.60 - 24.57
Shares Outstanding (Mil)37.73

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) 0.59
EPS w/o NRI ($) 0.59
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for RTRX

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Largest Insider Buys of the Week Apr 07 2014 
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP Apr 07 2014 
Three CEOs Reporting Large Insider Buys Apr 04 2014 
Steven Cohen Tops GuruFocus' Real Time Picks of the Week Apr 04 2014 
Morning Coffee: See Which Insiders are Buying Apr 04 2014 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 
Weekly CEO Buys Highlight: KMI, CLMS, RTRX, OPK, KO Mar 03 2014 
Weekly CEO Buys Highlight: RSE, RHP, RTRX, CLMS Jan 21 2014 

More From Other Websites
ETFs with exposure to Retrophin, Inc. : December 2, 2016 Dec 02 2016
Retrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : December 1, 2016 Dec 01 2016
Retrophin to Present at the BMO Capital Markets Healthcare Conference Nov 30 2016
Is Retrophin Inc (RTRX) A Good Stock To Buy? Nov 28 2016
Ligand's Partner Retrophin Provides New Data on Sparsentan Nov 22 2016
Here's Why Retrophin's DUET Data Pushes Upside To 129% Nov 21 2016
Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental... Nov 19 2016
Retrophin, Inc. :RTRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
Retrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : November 17, 2016 Nov 17 2016
RETROPHIN, INC. Financials Nov 15 2016
Horizon Pharma PLC (HZNP), Flamel Technologies S.A. (ADR) (FLML) & More: Why Should You Consider... Nov 14 2016
Retrophin Reaches Agreement with FDA under Special Protocol Assessment for Pivotal Trial Evaluating... Nov 10 2016
Retrophin Reaches Agreement with FDA under Special Protocol Assessment for Pivotal Trial Evaluating... Nov 10 2016
Retrophin reports 3Q loss Nov 03 2016
Retrophin reports 3Q loss Nov 03 2016
RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 03 2016
Retrophin Reports Third Quarter 2016 Financial Results Nov 03 2016
Retrophin Reports Third Quarter 2016 Financial Results Nov 03 2016
Q3 2016 Retrophin Inc Earnings Release - After Market Close Nov 03 2016
Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral... Oct 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)